Allscripts Healthcare Solutions

Veradigm, Inc. engages in the provision of clinical, financial, and operational results services. It operates through the Provider and Veradigm segments. The Provider segment includes the hospitals and health systems, ambulatory, CarePort, FollowMyHealth, EPSiTM, EISClassics, and 2bPrecise strategic business units. The firm solutions include All EMRs, All Population Health Management, Patient Engagement, and Precision Medicine. The company was founded in 1986 and is headquartered in Chicago, IL.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Here's why the healthcare technology provider narrowly beat analysts' earnings estimates in Q2 but missed on revenue expectations.

What's Behind Allscripts' Mixed Q2 Results

Allscripts Healthcare Solutions, Inc. (MDRX) CEO Paul Black on Q2 2019 Results - Earnings Call Transcript

AllScripts (MDRX) delivered earnings and revenue surprises of 6.25% and -0.72%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

AllScripts Healthcare (MDRX) Beats Q2 Earnings Estimates

Cerner

MDRX vs. CERN: Which Stock Is the Better Value Option?

MDRX vs. CERN: Which Stock Should Value Investors Buy Now?

Allscripts (MDRX) is gaining steadily from strategic acquisitions and solid prospects in Sunrise EHR platform. However, integration risks remain a woe.

Here's Why You Should Retain Allscripts (MDRX) Stock Now

ZappRx has found a buyer: Publicly-traded health IT company AllScripts.

Allscripts is buying ZappRx, a prescription drug start-up

AllScripts (MDRX) reported earnings 30 days ago. What's next for the stock?

Why Is AllScripts (MDRX) Up 1.6% Since Last Earnings Report?

Allscripts (MDRX) Q1 results gain from growth in bookings and solid show by client services segment. Contraction in margins remains a woe.

Allscripts (MDRX) Q1 Earnings Beat Estimates, Revenues Miss

Allscripts Healthcare Solutions, Inc. (MDRX) CEO Paul Black on Q1 2019 Results - Earnings Call Transcript

AllScripts (MDRX) delivered earnings and revenue surprises of 14.29% and -1.02%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

AllScripts Healthcare (MDRX) Q1 Earnings Surpass Estimates

AllScripts (MDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: AllScripts Healthcare (MDRX) Q1 Earnings Expected to Decline

AllScripts (MDRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is AllScripts (MDRX) Down 17.1% Since Last Earnings Report?

News for Allscripts Healthcare Solutions Stock (MDRX)